Dennis Moledina, MD PhD

A brief thread on our recently published work on CXCL9 as a diagnostic biomarker for acute tubulointerstitial nephritis (AIN) jci.org/articles/view/… @jclinicalinvest @YaleMed @YaleIMed @YaleNephrology @KidneydrChirag @fperrywilson

1 in 5 patients develops acute kidney injury (AKI) within the first year of starting cancer immunotherapy. Researchers are investigating whether checkpoint inhibitors are causing acute interstitial nephritis. Read more in the Q&A with @dmoledina. medicine.yale.edu/internal-medic…

@PAWellingMD @KidneydrChirag The value of KPMP is starting…congrats…great work. mdcalc.com/calc/10550/acu…

New @hopkinsneph study uses new electronic diagnostic model as an alternative to kidney biopsies to predict AIN. @KidneydrChirag bit.ly/4hKaEXK

This important advance was greatly enabled by superstars who are developing kidney biopsy registries at their institutions @dmoledina @StevenMenez

I hope people will use the AIN calculator to differentiate AIN from ATN on AKI consults. Let us know if you have questions or additional suggestions. @dmoledina

📸 Tiffany B from @lloydcantley1 presenting her IMC work @KPMProject 📸 Sagar S and @KidneydrChirag presenting a poster together @dmoledina @fperrywilson 📸 Bhavya B focused on her work in @lloydcantley1 lab 📸 More HRS data from @jmbnephdoc So much to see! #KidneyWk

Dr. Leyuan Xu presenting the Immune Landscape of AKI in 6B at @ASNKidney #KidneyWk now! Excellent talk and excellent summary slide! @lloydcantley1 @dmoledina @PKDSteve @KidneydrChirag

📸 @meganlebaker giving her first oral presentation at @ASNKidney #KidneyWk this afternoon, on her work characterizing immune-tubulointerstitial interactions in AIN and ATI! @lloydcantley1 @dmoledina

New in @JASN_News : external validation of a diagnostic model for predicting biopsy-proven AIN increased AUC of clinicians' prebiopsy suspicion for AIN by 0.10 to 0.77! Awesome tool! @dmoledina @Nephronette @fperrywilson @KidneydrChirag @YaleIMed journals.lww.com/jasn/abstract/…

Accurate diagnosis of acute tubulointerstitial nephritis (AIN) often requires a kidney biopsy. This study found that an AIN diagnostic model retained discrimination in two validation cohorts but needed recalibration to account for local AIN prevalence. bit.ly/JASN0556 @dmoledina @fperrywilson @kidneydrchirag @Nephronette @oconnkyle @StevenMenez

A new #clinicaltrial led by @YaleIMed's @dmoledina seeks to use biomarkers to detect when kidney injury results from #immunotherapy complications, reducing treatment interruptions for patients with #cancer. Learn more in a YSM Q&A: brnw.ch/21wOtYY

@hswapnil @NephroGuy @rmohty @onconephsociety We had urine PDL1 (not PD1) in our olink proteomics data. 1.7 fold higher in AIN (pval=0.007, qval=0.03). CXCL9 was 7.6-fold higher in AIN.

@hswapnil @NephroGuy @rmohty @onconephsociety very cool study - urine sPD1 could be a biomarker of ICI-AIN vs. other AIN (2.7 fold higher). i can't figure out if there is any difference in non-ICI-AIN vs. ATN. We didn't measure this so can't really tell which one performs better (CXCL9 vs. PD1).

Urinary soluble PD-1 as a biomarker of Checkpoint Inhibitor induced acute tubulointerstitial nephritis academic.oup.com/ckj/advance-ar…

@SWadhwaniMD @NU_Nephrology @OhioStateNeph @Rush_Nephrology Congratulations!!

That 1st promotion is pretty special ☺️ Thank you to all my mentors @NU_Nephrology @OhioStateNeph @Rush_Nephrology 💜❤️💚who helped me on this journey as well as my incredible #GN tribe, near & far 🌎

@hswapnil @NephroSeeker @NephJC This is the really good study looking at PPI-AIN /PPI-AKI. 2-3 fold higher hazard of both but low incidence of bx-proven AIN (though certainly some could’ve been missed). pubmed.ncbi.nlm.nih.gov/26389094/

@NephroSeeker @NephJC AKI - I am pretty sure - PPIs sometimes cause AIN - we miss some/many of PPI induced AIN Wish we had a better way of diagnosis AIN without a biopsy right @dmoledina ? #NephJC

In the placebo group, a single AKI event occurred in 92 participants. In the pantoprazole group, the incidence was 0.9% in 81 participants. That is a pretty small number of events to make any definitive association. #NephJC

Dr. Dennis Moledina @dmoledina discusses his research into identifying and validating #biomarkers for the diagnosis of acute interstitial #nephritis. Watch his #GrandRounds talk now youtu.be/Bgk9c7VCZmc. #kidneycancer @SmilowCancer @YaleMed @YNHH

Dr Erin Barreto @erin_barreto - medication management in AKI: moving beyond “medications reviewed” #NKFClinicals

Multidisciplinary Care of Patients Hospitalized with AKI - @javo_neyra kicking off the session #NKFClinicals

#NKFClinicals interprofessional care of patients with AKI: it takes a village @JeffNeph @javo_neyra @erin_barreto

Dr Turner @JeffNeph talking about updates in cardiorenal syndrome #NKFClinicals

@VelezNephHepato Next from the Mayo Clinic - Dr. Nelson Leung. #NKFClinicals cancer and chemotherapy associated kidney injury

Happening now at #NKFClinicals AKI syndromes: special considerations with @VelezNephHepato @JeffNeph Dr Nelson Leung. Room 104b